# Ludwig Center at Harvard [Go to HMS chevron\_right](http://hms.harvard.edu/) ![ludwig3.jpg](/sites/g/files/omnuum5451/files/styles/hwp_21_9__1920x825/public/ludwigharvard/files/ludwig3.jpg?itok=jGWGensw) The Ludwig Center at Harvard Medical School brings together investigators from across Harvard to develop strategies to overcome barriers that limit the efficacy of current and emerging cancer therapies. ## Explore - [Learn about Ludwig Center at Harvard ](https://prod-ludwigharvard.drupalsites.harvard.edu/overview) - Meet our [Team](/our-people) - Explore our [Science](/our-science) ## Participate - Check out our [News](/news) - [Submit](/submit-your-eventpublication) an event or publication ## Featured Publications Download 5 citations download- [BibTeX](/bibcite/export?pager_style=no_pager&number_of_items=5&sort_field=bibcite_year--desc&taxonomy_filters=&&&format=bibtex) - [EndNote X3 XML](/bibcite/export?pager_style=no_pager&number_of_items=5&sort_field=bibcite_year--desc&taxonomy_filters=&&&format=endnote8) - [EndNote 7 XML](/bibcite/export?pager_style=no_pager&number_of_items=5&sort_field=bibcite_year--desc&taxonomy_filters=&&&format=endnote7) - [Endnote tagged](/bibcite/export?pager_style=no_pager&number_of_items=5&sort_field=bibcite_year--desc&taxonomy_filters=&&&format=tagged) - [Marc](/bibcite/export?pager_style=no_pager&number_of_items=5&sort_field=bibcite_year--desc&taxonomy_filters=&&&format=marc) - [PubMedId](/bibcite/export?pager_style=no_pager&number_of_items=5&sort_field=bibcite_year--desc&taxonomy_filters=&&&format=pubmed_id) - [RIS](/bibcite/export?pager_style=no_pager&number_of_items=5&sort_field=bibcite_year--desc&taxonomy_filters=&&&format=ris) ### 2026 Lee, Y. S. *et al.* [Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.](https://pubmed.ncbi.nlm.nih.gov/41815287/) *Blood neoplasia* **3**, 100202 (2026). Lee, Y. S. *et al.* [Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.](https://pubmed.ncbi.nlm.nih.gov/41815287/) *Blood neoplasia* **3**, 100202 (2026). - add\_circle do\_not\_disturb\_on Abstract Targeted therapies, such as the BCL-2 inhibitor venetoclax, have expanded the treatment options for patients with acute myeloid leukemia (AML), but survival remains poor because of drug resistance and disease relapse. We found that the translation... Wu, B. *et al.* [TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.](https://pubmed.ncbi.nlm.nih.gov/41932810/) *Journal for immunotherapy of cancer* **14**, (2026). Wu, B. *et al.* [TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.](https://pubmed.ncbi.nlm.nih.gov/41932810/) *Journal for immunotherapy of cancer* **14**, (2026). - add\_circle do\_not\_disturb\_on Abstract **BACKGROUND:** Immune exclusion inhibits antitumor immunity and response to immunotherapy, but its mechanisms remain poorly defined. In triple-negative breast cancer (TNBC), an aggressive and generally immune-rich subtype, an immune-cold microenvironment... Goyette, M.-A. *et al.* [HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies.](https://pubmed.ncbi.nlm.nih.gov/41925564/) *Cancer discovery* (2026) doi:10.1158/2159-8290.CD-25-1459. Goyette, M.-A. *et al.* [HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies.](https://pubmed.ncbi.nlm.nih.gov/41925564/) *Cancer discovery* (2026) doi:10.1158/2159-8290.CD-25-1459. - add\_circle do\_not\_disturb\_on Abstract Intratumor heterogeneity for HER2 in HER2-positive breast cancer is a driver of resistance to HER2-targeted therapies. The advancement of treatments for HER2 heterogeneous tumors has been hindered by the lack of preclinical models that accurately mimic... Lee, S. M. *et al.* [Host microRNA-31-5p regulates KHDRBS3 expression and modulates viral gene expression during KSHV lytic reactivation.](https://pubmed.ncbi.nlm.nih.gov/41931390/) *Cell reports* **45**, 117160 (2026). Lee, S. M. *et al.* [Host microRNA-31-5p regulates KHDRBS3 expression and modulates viral gene expression during KSHV lytic reactivation.](https://pubmed.ncbi.nlm.nih.gov/41931390/) *Cell reports* **45**, 117160 (2026). - add\_circle do\_not\_disturb\_on Abstract Oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) employs a biphasic life cycle consisting of latency and lytic replication to achieve lifelong infection. Despite its essential role in KSHV persistence and tumorigenicity, much remains unknown about... Meylan, M. *et al.* [Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial.](/publication/persistent-t-cell-activation-and-cytotoxicity-against-glioblastoma-following-single) *Cell* **189**, 1287–1304.e18 (2026). Meylan, M. *et al.* [Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial.](/publication/persistent-t-cell-activation-and-cytotoxicity-against-glioblastoma-following-single) *Cell* **189**, 1287–1304.e18 (2026). - add\_circle do\_not\_disturb\_on Abstract A recent first-in-human clinical trial demonstrated that survival in glioblastoma (GBM) patients following rQNestin34.5v.2 oncolytic virus treatment was associated with immune activation signatures. This study was registered at ClinicalTrials.gov... [ More arrow\_circle\_right ](/publications) ## Latest News [### DF/HCC Incubator Awards: Terms specific to Ludwig-funded Awards ](/news/dfhcc-incubator-awards-terms-specific-ludwig-funded-awards) August 31, 2023 Anticipated Terms and Conditions for DF/HCC Incubator Awards funded through Ludwig Center at Harvard include: Budget: Funding may be used only for research directly related to and budgeted under the project. Budget items may include personnel expenses... [ More arrow\_circle\_right ](/news)